Catalyst Pharmaceuticals announced that it has commenced an underwritten public offering of $150M of its common stock. BofA Securities, Citigroup, Piper Sandler & Co., Cantor, and Truist Securities are acting as bookrunners for the offering. Oppenheimer & Co. is acting as co-manager for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CPRX:
- Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
- Salesforce upgraded, Chipotle downgraded: Wall Street’s top analyst calls
- Catalyst Pharmaceuticals initiated with an Outperform at Oppenheimer
- Catalyst Pharmaceuticals announces submission of FIRDAPSE NDA in Japan
- Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma
